CVS Health Corporation $CVS Shares Purchased by Kestra Advisory Services LLC

Kestra Advisory Services LLC boosted its stake in shares of CVS Health Corporation (NYSE:CVS) by 9.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 77,785 shares of the pharmacy operator’s stock after buying an additional 6,580 shares during the quarter. Kestra Advisory Services LLC’s holdings in CVS Health were worth $5,587,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in CVS. TOWER TRUST & INVESTMENT Co boosted its stake in shares of CVS Health by 0.8% during the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after acquiring an additional 132 shares in the last quarter. CYBER HORNET ETFs LLC increased its stake in CVS Health by 4.1% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 134 shares in the last quarter. LS Investment Advisors LLC raised its holdings in CVS Health by 3.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after purchasing an additional 135 shares during the last quarter. Moss Adams Wealth Advisors LLC raised its holdings in CVS Health by 4.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after purchasing an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC boosted its position in CVS Health by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after purchasing an additional 136 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist Financial raised its price target on CVS to $118 and reiterated a buy rating, reinforcing bullish analyst sentiment and suggesting additional upside from current levels.
• Positive Sentiment: CVS Caremark reached a global settlement with the FTC that CVS says advances transparency and affordability in prescription drug pricing, potentially easing a major legal overhang for the pharmacy-benefit manager business. Article Title
• Positive Sentiment: Reports highlighting CVS as a 52-week high stock and a potentially attractive long-term value play are keeping momentum traders and value investors interested.
• Neutral Sentiment: CVS continued to promote Aetna provider survey results showing improved payer trust and the benefits of digital tools, which is supportive for the healthcare-services narrative but not a major immediate stock catalyst. Article Title
• Neutral Sentiment: CVS also affirmed its dividend and expanded GLP-1 support programs, which helps the investment case, though the market may still be waiting to see whether those efforts meaningfully improve employer economics and utilization trends.
• Negative Sentiment: Wall Street Zen downgraded CVS to Hold, and the stock is trading near its recent high, which could prompt some investors to question near-term valuation after a strong run.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on CVS shares. Truist Financial raised their price target on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley boosted their price objective on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Argus raised their target price on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. DA Davidson lifted their target price on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, TD Cowen increased their price target on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Twenty-one research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average target price of $105.38.

CVS Health Price Performance

Shares of NYSE:CVS opened at $106.01 on Thursday. The company has a market cap of $135.26 billion, a P/E ratio of 46.70, a P/E/G ratio of 1.04 and a beta of 0.61. The business has a fifty day simple moving average of $98.25 and a 200-day simple moving average of $84.79. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $107.94. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the prior year, the business posted $2.25 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts forecast that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last three months. Corporate insiders own 0.85% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.